Canaccord Genuity Maintains Buy Rating and Raises CeriBell Price Target to $33
Canaccord Genuity reaffirmed its 'Buy' rating on CeriBell and increased its price target to $33 from $26.
Stocks · News reference
Ceribell Says FDA Cleared Brain Monitoring Software Update With No Age Restriction, Expects Rollout In 1H 2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BofA Securities Adjusts Price Target on CeriBell to $31 From $26
BofA Securities has increased its price target for CeriBell, Inc. following the company's recent financial disclosures.
CeriBell, Inc. Reports Third Quarter 2026 Financial Results
CeriBell reported $29.3 million in revenue for the third quarter of 2026, representing a 30% year-over-year increase, and raised its full-year revenue outlook.
8-K filing — Ceribell, Inc. (CBLL)
Filed: 2026-11-03 AccNo: 0001193125-26-445487 Size: 652 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
CeriBell Announces Commercial Launch of Delirium Monitoring Solution
CeriBell has launched a new delirium monitoring feature for its point-of-care EEG platform, allowing for integrated seizure and delirium monitoring.
CeriBell CFO to Participate in Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
CeriBell, Inc. announced that its Chief Financial Officer, Scott Blumberg, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum.